Jones Trading initiates coverage on Aardvark Therapeutics stock with Buy rating
PositiveFinancial Markets

Jones Trading has started coverage on Aardvark Therapeutics, giving it a 'Buy' rating. This is significant as it indicates confidence in Aardvark's potential for growth and success in the market, which could attract more investors and boost the company's stock performance.
— Curated by the World Pulse Now AI Editorial System